Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal

View ORCID ProfileIrina Kislaya, Pedro Casaca, View ORCID ProfileVítor Borges, Carlos Sousa, Bibiana I. Ferreira, Eugénia Fernandes, Carlos Matias Dias, Sílvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, View ORCID ProfileDaniela Santos, António Maia Gonçalves, Luís Vieira, View ORCID ProfileJoão Paulo Gomes, Pedro Pinto Leite, View ORCID ProfileBaltazar Nunes, Ausenda Machado, André Peralta-Santos
doi: https://doi.org/10.1101/2022.07.25.22277996
Irina Kislaya
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Irina Kislaya
  • For correspondence: Irina.kislaya@insa.min-saude.pt
Pedro Casaca
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vítor Borges
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vítor Borges
Carlos Sousa
6Unilabs, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bibiana I. Ferreira
7Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal;Faculty of Medicine and Biomedical Sciences (FMCB), Campus de Gambelas, University of Algarve, Faro, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugénia Fernandes
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Matias Dias
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sílvia Duarte
8Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José Pedro Almeida
6Unilabs, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inês Grenho
7Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal;Faculty of Medicine and Biomedical Sciences (FMCB), Campus de Gambelas, University of Algarve, Faro, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luís Coelho
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita Ferreira
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrícia Pita Ferreira
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joana Isidro
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel Pinto
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luís Menezes
6Unilabs, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Sobral
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Nunes
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Santos
8Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniela Santos
António Maia Gonçalves
6Unilabs, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luís Vieira
8Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
João Paulo Gomes
5Genomics and Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for João Paulo Gomes
Pedro Pinto Leite
4Direção de Serviços de Informação e Análise, Direção-geral da Saúde, Lisbon, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baltazar Nunes
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Baltazar Nunes
Ausenda Machado
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André Peralta-Santos
1Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal
2NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa
3Comprehensive Health Research Centre (CHRC), Universidade NOVA de Lisboa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background In a context of multiple Omicron lineages circulation, it is relevant to clarify the effect of vaccination and previous infections on the risk of infection and severe post-infection outcomes.

Methods Using electronic health records and SARS-CoV-2 laboratory surveillance data, we conducted a case-case and a cohort study covering the period of Omicron BA.2/BA.5 lineage replacement in Portugal, to compare vaccine effectiveness of complete primary and booster dose against infection, COVID-19 hospitalization, and mortality. Variant classification was performed through whole-genome sequencing (WGS) or Spike Gene Target Failure (SGTF).

Findings Between April 25 and June 10, 2022, within a total of 27702 collected samples, 55.5% were classified as BA.2 and the remaining as BA.5. We observed no evidence of reduced vaccine effectiveness for the primary complete vaccination (OR=1.07, CI95%:0.93-1.23) or booster dose vaccination (OR=0.96, CI95%:0.84-1.09) against BA.5 infection compared with BA.2. The protection against reinfection was inferior in BA.5 cases when compared with BA.2 (OR=1.44; CI95%:1.30-1.60). Among those infected with BA.5, booster vaccination was associated with 77% and 88% of reduction in risk of COVID-19 hospitalization and death, respectively, while higher risk reduction was found for BA.2 cases, with 93% and 94%, respectively.

Interpretation This study shows that the SARS-CoV-2 Omicron BA.5 lineage is associated with higher odds of reinfection compared with Omicron BA.2, regardless of the vaccination status.

Although less effective compared with BA.2, COVID-19 booster vaccination still offers substantial protection against severe outcomes following BA.5 infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The acquisition of sequencing equipment/reagents used in this study by INSA was partially funded by the HERA project (Grant/2021/PHF/23776) supported by the European Commission through the European Centre for Disease Control, and also partially funded by the GenomePT project (POCI-01-0145-FEDER-022184), supported by COMPETE 2020 Operational Programme for Competitiveness and Internationalisation (POCI), Lisboa Portugal Regional Operational Programme (Lisboa2020), Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and by the Portuguese Science and Technology Foundation (FCT).” ABC laboratory received public funding through the Project ALG-D2-2021-06 VISITOR (VarIants Screen In souThern pORtugal) Monitoring Variants of Concern (VOC) in Southern Portugal and the Portuguese Science and Technology Foundation national support through CHRC (UIDP/04923/2020) The funders had no role in study design, data collection, data analysis, interpretation of the data, writing of the report, or decision to submit the paper for publication. The findings, opinions and conclusions described in this article reflect the views of the authors only.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical Statement The genomic surveillance of SARS-CoV-2 in Portugal is regulated by the Assistant Secretary of State and Health Executive Order (Despacho n. 331/2021 of January 11, 2021). The study protocol received the clearance of the Ethics Committee of Instituto Nacional de Saude Dr Ricardo Jorge on June 15, 2022.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding The acquisition of sequencing equipment/reagents used in this study by INSA was partially funded by the HERA project (Grant/2021/PHF/23776) supported by the European Commission through the European Centre for Disease Control, and also partially funded by the GenomePT project (POCI-01-0145-FEDER-022184), supported by COMPETE 2020 – Operational Programme for Competitiveness and Internationalisation (POCI), Lisboa Portugal Regional Operational Programme (Lisboa2020), Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and by the Portuguese Science and Technology Foundation (FCT).”

  • ABC laboratory received public funding through the Project ALG-D2-2021-06 VISITOR (VarIants Screen In souThern pORtugal) - Monitoring Variants of Concern (VOC) in Southern Portugal and the Portuguese Science and Technology Foundation national support through CHRC (UIDP/04923/2020)

  • Conflict of interest: None

  • Role of the funding source The funders had no role in study design, data collection, data analysis, interpretation of the data, writing of the report, or decision to submit the paper for publication. The study was designed by AM, IK, BN, CD, APS and PC. Data collection was performed by JPG, VB, LC, RF, JI, MP, DS, AN, DSa, SD, LV, CS, JPA, LM, BF, ACSS, APS, EF, PPF. Data analysis was completed by IK and verified by APS. IK, PC and APS wrote the first draft of the manuscript. Data interpretation was performed by IK, APS, PC and AM. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved. IK is responsible for submitting the manuscript. The findings, opinions and conclusions described in this article reflect the views of the authors only. ECDC is in no way responsible for the information contained in this article or for any use that may be made of this information.

Data Availability

Data used in the present study can be available upon reasonable request from the data owner

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted July 25, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal
Irina Kislaya, Pedro Casaca, Vítor Borges, Carlos Sousa, Bibiana I. Ferreira, Eugénia Fernandes, Carlos Matias Dias, Sílvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, Daniela Santos, António Maia Gonçalves, Luís Vieira, João Paulo Gomes, Pedro Pinto Leite, Baltazar Nunes, Ausenda Machado, André Peralta-Santos
medRxiv 2022.07.25.22277996; doi: https://doi.org/10.1101/2022.07.25.22277996
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal
Irina Kislaya, Pedro Casaca, Vítor Borges, Carlos Sousa, Bibiana I. Ferreira, Eugénia Fernandes, Carlos Matias Dias, Sílvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, Daniela Santos, António Maia Gonçalves, Luís Vieira, João Paulo Gomes, Pedro Pinto Leite, Baltazar Nunes, Ausenda Machado, André Peralta-Santos
medRxiv 2022.07.25.22277996; doi: https://doi.org/10.1101/2022.07.25.22277996

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8989)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1904)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)